Wuhan Hvsen Biotechnology Co Ltd - Asset Resilience Ratio
Wuhan Hvsen Biotechnology Co Ltd (300871) has an Asset Resilience Ratio of 9.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Wuhan Hvsen Biotechnology Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Wuhan Hvsen Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See 300871 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Wuhan Hvsen Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300871 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥283.81 Million | 9.59% |
| Total Liquid Assets | CN¥283.81 Million | 9.59% |
Asset Resilience Insights
- Limited Liquidity: Wuhan Hvsen Biotechnology Co Ltd maintains only 9.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wuhan Hvsen Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Wuhan Hvsen Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC |
Biotechnology | 91585.83% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
Annual Asset Resilience Ratio for Wuhan Hvsen Biotechnology Co Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Wuhan Hvsen Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.67% | CN¥200.97 Million ≈ $29.41 Million |
CN¥3.01 Billion ≈ $441.14 Million |
-3.56pp |
| 2023-12-31 | 10.23% | CN¥304.26 Million ≈ $44.52 Million |
CN¥2.98 Billion ≈ $435.40 Million |
-1.87pp |
| 2022-12-31 | 12.10% | CN¥361.68 Million ≈ $52.92 Million |
CN¥2.99 Billion ≈ $437.40 Million |
+11.00pp |
| 2021-12-31 | 1.10% | CN¥30.22 Million ≈ $4.42 Million |
CN¥2.74 Billion ≈ $401.19 Million |
-12.63pp |
| 2020-12-31 | 13.73% | CN¥240.63 Million ≈ $35.21 Million |
CN¥1.75 Billion ≈ $256.41 Million |
-- |
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various vet… Read more